Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies.

ABSTRACT:

Background

Hematopoietic malignancies are extremely common in pet dogs and represent nearly 30% of the malignancies diagnosed in this population each year. Clinicians commonly use existing tools such as physical exam findings, radiographs, ultrasound and baseline blood work to monitor these patients for treatment response and remission. Circulating biomarkers, such as prostate specific antigen or carcinoembryonic antigen, can be useful tools for monitoring treatment response and remission status in human cancer patients. To date, there has a been a lack of useful circulating biomarkers available to veterinary oncology patients.

Methods

Circulating plasma nucleosome concentrations were evaluated at diagnosis, throughout treatment and during remission monitoring for 40 dogs wi

SUBMITTER: Wilson-Robles H 

PROVIDER: S-EPMC10171669 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature